| Similar Articles |
|---|
 |
The Motley Fool
December 28, 2006
Brian Lawler |
Money Falling From the Skye Investors are wondering what to make of drug developer SkyePharma announcing yesterday that it was raising more cash via financing and also upping the costs of its Flutiform asthma treatment development program.   |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
December 1, 2005
Jack Uldrich |
How High Is SkyePharma? SkyePharma's technology can create not only more and better new drugs but also reformulate old ones. The company's recent run up to $9 per share still has some legs. |
The Motley Fool
December 31, 2007
Brian Lawler |
The Anatomy Of An Approved Drug An independent audit by the FDA provides a useful summary of the characteristics of drugs approved by the agency. |
The Motley Fool
July 6, 2007
Brian Orelli |
Pain-Free Phase 2 Data Anesiva's pain medication is moving up the clinical trial ladder. The Adlea results are very promising, but investors should look at the state of the entire company before investing. |
Chemistry World
September 25, 2013
Phillip Broadwith |
New respiratory drugs neck and neck A flurry of regulatory approvals has seen three new drugs approved for asthma and chronic obstructive pulmonary disease in the European and Japanese markets. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
The Motley Fool
December 28, 2004
Charly Travers |
It's All in the Delivery If too much risk makes you queasy, these drug companies are for you. SkyePharma... DepoMed... |
The Motley Fool
August 31, 2007
Brian Orelli |
Guidelines to Stop the Wheezing Investors, new asthma guidelines will affect some drug makers. The FDA isn't the only organization that affects how well drugs do in the marketplace. |
The Motley Fool
July 18, 2005
Karl Thiel |
Stocks That Make You Breathe Easier Allergies and asthma are big markets that several firms aim to tackle. Investors, take note. |
Managed Care
March 2004
Christine A. Sorkness |
IgE-Blocking Therapy for Difficult-to-Treat Asthma: A Brief Review Omalizumab, a novel therapy that targets specific steps in the inflammatory cascade of asthma, may benefit the hard-to-treat patient. |
